Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

AstraZeneca

1,375.5

 

SEK

 

+1.4 %

Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
+1.4%
-1.61%
-15.2%
-4.91%
-6.49%
-14.94%
+4.2%
+34.75%
+7,426.47%

AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and marketing of prescription drugs, primarily for the treatment of diseases in the areas of therapy that affect the respiratory tract, cardiovascular / metabolism, and cancer. In addition to its main operations, the company is also active in autoimmunity, neuroscience, and infection. AstraZeneca is active in all global regions and is headquartered in Cambridge.

Read more
Market cap
2.13T SEK
Turnover
646.09M SEK
Revenue
596.39B
EBIT %
18.5 %
P/E
27.47
Dividend yield-%
2.49 %
Financial calendar
29.7
2025

Interim report Q2'25

All
Press releases
ShowingAll content types
Regulatory press release2/28/2025, 1:06 PM

AstraZeneca: Enhertu recommended in EU in post-ET breast cancer

AstraZeneca
Regulatory press release2/6/2025, 7:00 AM

AstraZeneca: Final Results

AstraZeneca
Regulatory press release10/7/2024, 8:30 AM

AstraZeneca licenses lipid lowering Lp(a) asset

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/7/2024, 11:00 AM

AstraZeneca: Notice of AGM

AstraZeneca
Regulatory press release2/21/2024, 7:00 AM

AstraZeneca: Filing of Form 20-F with SEC

AstraZeneca
Regulatory press release11/9/2023, 7:00 AM

AstraZeneca: 9M and Q3 2023 results

AstraZeneca
Press release7/25/2022, 6:11 AM

AstraZeneca: Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

AstraZeneca
Press release7/25/2022, 6:06 AM

AstraZeneca: Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

AstraZeneca
Press release7/25/2022, 6:01 AM

AstraZeneca: Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

AstraZeneca
Regulatory press release7/19/2022, 6:01 AM

AstraZeneca: Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

AstraZeneca
Press release5/16/2022, 6:00 AM

AstraZeneca: PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation

AstraZeneca
Regulatory press release12/14/2020, 9:00 AM

AstraZeneca to acquire Alexion Pharmaceuticals Inc

AstraZeneca
Regulatory press release12/3/2019, 9:00 AM

AstraZeneca divests Seroquel rights: US and Canada

AstraZeneca
Regulatory press release10/23/2018, 9:00 AM

AstraZeneca Extends Innate Pharma Collaboration

AstraZeneca
Regulatory press release10/1/2018, 9:00 AM

AstraZeneca PLC Announces Agreement with Cheplapharm for rights to Atacand in 28 European countries completed

AstraZeneca
Regulatory press release9/24/2018, 9:00 AM

Farxiga gets positive result in DECLARE-TIMI 58

AstraZeneca
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team